TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By The Schall Law Firm
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Alector's Phase 3 clinical trial for latozinemab in frontotemporal dementia failed to meet primary endpoints, causing a 50% stock price drop and triggering a potential shareholder lawsuit.

Insights
ALEC   negative

Failed clinical trial for key drug candidate, significant stock price decline, and potential legal action from shareholders indicate substantial negative business impact